Over the last decade, we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC) which is an advanced and lethal form of prostate cancer. A deeper understanding of its underlying biology has led to the development of compounds targeting the androgen signaling pathway and the immune system, as well as taxanes and radiopharmaceuticals.

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational research. We also play a leading role in many of the clinical trials that we run.